- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01513187
Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma
Phase I/II Prospective, Open Label and Multicentric Clinical Trial to Determine the Recommended Dose (Phase I) and Efficacy of Pazopanib in Combination With Interferon Alfa 2-A (Phase II), in Patients With Advanced Renal Cell Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08003
- Hospital del Mar
-
Barcelona, Spain, 08036
- Hospital Clinic
-
Madrid, Spain, 28040
- Hospital Clinico San Carlos
-
Madrid, Spain, 28041
- Hospital Universitario 12 de Octubre
-
Oviedo, Spain, 33066
- Hospital Central de Asturias
-
Palma, Spain, 07010
- Hospital Son Espases
-
Pamplona, Spain, 31008
- Clinica Univ. Navarra
-
Sevilla, Spain, 41013
- Hospital Virgen del Rocío
-
Sevilla, Spain, 41009
- Hospital Virgen de la Macarena
-
Toledo, Spain, 45004
- Hospital Virgen de la Salud
-
Valencia, Spain, 46009
- IVO
-
-
Barcelona
-
Hospitalet de Llobregat, Barcelona, Spain, 08097
- Instituto Catalán de Oncología, Hospitalet del Llobregat
-
-
Sanchinarro - Madrid
-
Sanchinarro, Sanchinarro - Madrid, Spain, 28050
- Centro Integral Oncológico Clara Campal
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent
- Age ≥ 18 years.
- Patients diagnosed histologically clear cell carcinoma of the kidney metastatic or unresectable locally advanced, previously untreated. However, in Phase I may include patients with primary tumors other than renal cell can benefit from these drugs and patients with renal cell carcinoma treated before.
- Performance status (ECOG) 0-1.
- Patients must have measurable disease by RECIST criteria V 1.1. Progression should be documented in the two months prior to study entry.
- Patients may not have received prior treatment with anti-VEGF agents, mTOR inhibitors or cytokines. However, in Phase I may include patients who have received any previous treatment.
- Paraffin tumor sample should be available and collection of serum from all subjects for biomarker analysis previously and / or during treatment with study medication.
- Adequate Hematologic, liver and kidney functions.
- Women of childbearing potential must be using an effective method of birth control (abstinence, any intrauterine device [IUD] published data showing that the expected minimum rate of failure is less than 1% per year, or any other method the published data show that the expected minimum rate of failure is less than 1% per year) before inclusion in the study and continue using it during the same six months after completion. Women of childbearing age should get a negative pregnancy test in urine or serum (minimum sensitivity 25 IU / L or equivalent units of beta fraction of human chorionic gonadotropin [β-HCG]) during the seven days prior to the randomization.
- Able to swallow oral compound.
- Willingness and ability to attend scheduled visits, to follow the treatment schedule and to undergo clinical trials and other study procedures
Exclusion Criteria:
History of prior malignancies diagnosed or treated over the past 5 years except basal cell skin cancer or prostate cancer incidentally detected previously treated. However, patients with a history of malignancy but free of the disease over the past 5 years, or patients with a history of nonmelanoma skin carcinoma-completely-resected or carcinoma in situ treated successfully can participate in the study .
In Phase I, patients diagnosed with other previous or concomitant malignant diseases can be included.
- Presence of metastases in the central nervous system (CNS) or leptomeningeal carcinomatosis, except for patients with previously treated CNS metastases, asymptomatic and have not needed corticosteroids or anticonvulsant drugs in the 3 months prior to administering the first dose of the drug under study. Only is required CNS imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI]) if clinically indicated or if the individual has a history of CNS metastases.
Clinically significant gastrointestinal disorders may increase the risk of gastrointestinal bleeding including, but not limited to:
Active peptic ulcer disease Known metastatic lesions with probable intraluminal bleeding Inflammatory bowel disease (ulcerative colitis, Crohn's disease) or other gastrointestinal disorders with increased risk of perforation History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days before the start of study treatment.
Clinically significant gastrointestinal abnormalities may affect the absorption of the investigational product such as but not limited to:
Malabsorption syndrome Major resection of the stomach or small intestine Grade 3 diarrhea
- Patients with active infection or other disease or serious medical condition.
- Prolongation of the corrected QT wave (QTc)> 480 ms on baseline ECG according to the Bazett formula.
Subjects with a history of one or more of the following cardiovascular disease in the last 6 months prior to the inclusion in the study:
Angioplasty or stent placement Myocardial infarction Unstable Angina Coronary bypass surgery Symptomatic peripheral vascular disease Congestive heart failure Class II, III or IV New York Heart Association (NYHA)
Poorly controlled hypertension [defined as systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure stress (DBP) ≥ 90 mmHg] while the patient is on antihypertensive therapy.
Note: the commencement or adjustment of antihypertensive medication it is possible before the patient study start. In the baseline period measure blood pressure at least twice with a minimum interval of 24 hours. The mean values of SBP / DBP in each blood pressure reading should be <140/90 mmHg to include the subject in the study.
Background, in the last six months prior to the inclusion of stroke (including transient ischemic attacks), pulmonary embolism or deep vein thrombosis (DVT) untreated.
Note: may be included subjects with recent DVT who received anticoagulants for at least 6 months.
- Surgery or trauma in the last 28 days, or minor surgery (eg., Removal of central venous catheter) in the last 7 days prior to inclusion or unhealed wound, fracture, or ulcer.
- Evidence of active bleeding or bleeding diathesis.
- Hemoptysis within 6 weeks prior to inclusion.
- Pregnant or breastfeeding.
- Any medical condition (eg. Uncontrolled infection), psychiatric or other to be serious and / or unstable and may interfere with the safety of the patient, obtaining informed consent or compliance with study procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pazopanib + interferon
Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days. Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient |
Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days. Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose (MTD) - Phase I
Time Frame: Up to September 2012
|
The MTD is defined as the dose at wich two of the patients have experienced dose-limiting toxicity.
|
Up to September 2012
|
Efficacy, response rate (Phase II)
Time Frame: Up to July 2013
|
Response rate is defined as the percentage of patients with complete response or partial response confirmed according RECIST v.1.1
|
Up to July 2013
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival
Time Frame: Up to July 2013
|
Period between the start of treatment until the day in in wich the progression is confirmed by RECIST guidelines (version 1.1) or death from any cause.
|
Up to July 2013
|
Overall Survival
Time Frame: Up to December 2013
|
Period between the start of treatment and date of death from any cause.
|
Up to December 2013
|
Frequency of adverse events
Time Frame: Up to July 2013
|
Toxicity evaluation of the combination using the NCI-CTC Criteria version 3.0
|
Up to July 2013
|
Translational Substudy
Time Frame: Up to December 2013
|
To analyze the different biomarkers and their variations with clinical outcomes of patients.
|
Up to December 2013
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Xavier García del Muro, MD, Instituto Catalán de Oncología, Hospitalet del Llobregat
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Carcinoma
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Immunologic Factors
- Interferons
- Interferon-alpha
- Interferon alpha-2
Other Study ID Numbers
- SOGUG-2010-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Renal Cell Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Advanced Sarcomatoid Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Canadian Cancer Trials GroupActive, not recruitingUnresectable Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma | Metastatic Papillary Renal Cell Carcinoma | Locally Advanced Papillary Renal Cell CarcinomaUnited States, Canada
-
National Cancer Institute (NCI)Active, not recruitingClear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Locally Advanced Malignant Solid Neoplasm | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Locally Advanced Clear Cell Renal Cell CarcinomaUnited States
-
Mabwell (Shanghai) Bioscience Co., Ltd.Not yet recruitingAdvanced Clear Cell Renal Cell Carcinoma
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingChromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...United States
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRecruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell CarcinomaUnited States
-
ExelixisArcus Biosciences, Inc.RecruitingAdvanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid TumorsUnited States
-
Argos TherapeuticsTerminatedRenal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Advanced Renal Cell CarcinomaIsrael, Spain, United States, Czechia, Canada, Italy, Hungary, United Kingdom
-
Calithera Biosciences, IncCompletedMetastatic Renal Cell Carcinoma | Advanced Renal Cell CarcinomaUnited States, United Kingdom, Australia, France, Italy, Germany, Spain, New Zealand
Clinical Trials on Pazopanib + interferon alpha 2A
-
Kaohsiung Medical University Chung-Ho Memorial...Completed
-
University Hospital TuebingenDermatologic Cooperative Oncology GroupCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedBreast Cancer | Metastatic CancerUnited States
-
Huashan HospitalUnknown
-
BioGeneric PharmaXiamen Amoytop Biotech Co., Ltd.UnknownHepatitis C | Self EfficacyEgypt
-
Vir Biotechnology, Inc.Alnylam PharmaceuticalsActive, not recruitingChronic Hepatitis BAustralia, Hong Kong, Korea, Republic of, Malaysia, New Zealand, Thailand
-
The Wistar InstituteNational Institute of Allergy and Infectious Diseases (NIAID); Hoffmann-La... and other collaboratorsCompleted
-
Kaohsiung Medical University Chung-Ho Memorial...Completed
-
M.D. Anderson Cancer CenterCompleted